

H&K Health Dose: What to Expect in the 119th Congress – January 16, 2025

A weekly dose of healthcare policy news

The 119th Congress is firmly under way, with committee assignments for new and returning members being finalized this week. One of the critical factors that will shape healthcare policy in the next administration is the appointment of leaders to key federal agencies. Members of healthcare committees of jurisdiction in the U.S. Senate are actively meeting with key individuals nominated to lead major federal health agencies. Nominees will meet with staff and committee members in preparation for courtesy and confirmation hearings. Of note, Robert F. Kennedy Jr.'s nomination to be Secretary of the U.S. Department of Health and Human Services (HHS) may be delayed beyond the last week of January 2025 due to process delays. Additional nominees to lead sub-agencies will be announced in the coming weeks, and attention will soon turn to President-Elect Donald Trump's inauguration on Jan. 20, 2025.

President-Elect Trump has unveiled plans to swiftly implement an ambitious policy agenda in his upcoming term. He and his transition team have committed to making "sealing the border" a top priority immediately after his inauguration and extending the tax cuts established under the Tax Cuts and Jobs Act (TCJA) within his first 100 days in office. While certain policy goals can be achieved through executive orders (EOs), critical components of his economic agenda will require legislative action.

We will closely monitor the development of key healthcare issues on Capitol Hill and within federal agencies. In the meantime, we outline some important items for stakeholders to watch in this week's Health Dose as we prepare for what promises to be a pivotal year in healthcare.

LEGISLATIVE UPDATES

Budget Reconciliation – One Big, Beautiful Bill?

With narrow majorities in both the U.S. House of Representatives and Senate, Republicans lack the votes needed to overcome a Senate filibuster. As a result, they have pledged to rely on budget reconciliation – a procedural tool that enables certain fiscal measures to pass with a simple majority – to advance President-Elect Trump's economic agenda. Budget reconciliation was introduced under the Congressional Budget and Impoundment Control Act of 1974, and it was designed to align federal revenues and expenditures. It begins with Congress passing a budget resolution with reconciliation instructions to specific committees. These instructions outline the changes necessary to meet budgetary goals, including specific dollar figure targets. Once the committees submit their proposals, they are combined into a single bill for consideration.

A provision is considered extraneous under the Byrd Rule if it:

- Lacks Budgetary Impact: Fails to affect federal spending or revenue or does not modify the terms under which these are determined
- Violates Instructions: Increases spending or decreases revenue beyond what the committee's reconciliation instructions allow
- Falls Outside Committee Jurisdiction: Addresses matters outside the proposing committee's purview
- Has Incidental Budgetary Effects: Features non-budgetary aspects that overshadow its fiscal impact
- Increases Deficits Beyond the Budget Window: Results in deficits beyond the timeframe covered by the reconciliation measure
- Modifies Social Security: Proposes changes to Social Security, explicitly excluded from reconciliation bills



Only one reconciliation bill can be passed per fiscal year (FY). Because Congress has not passed a reconciliation bill for FY 2025, Republicans have the option of passing two in the upcoming term. It remains uncertain whether health-related provisions will be included, but measures such as introducing work requirements for Medicaid eligibility, Medicaid percapita caps or repealing the Medicare nurse staffing rule could reduce federal spending. These changes will likely qualify for reconciliation if Republicans choose to pursue them.

Government Funding and Health Package: Round Two

Republicans must also confront a looming March 14, 2025, deadline to extend government funding. There is still no agreement on topline numbers for FY 2025 funding levels. House Committee on Energy and Commerce Subcommittee on Health Chair Buddy Carter (R-Ga.) has signaled his desire to revisit and pass healthcare provisions that were included in, and then stripped out of, a larger December 2024 Continuing Resolution (CR). Programs and policies that were rolled back include, but are not limited to:

- **Medicare Physician Payments:** A 2.8 percent reduction in the Physician Fee Schedule (PFS) conversion factor (CF) which took effect on Jan. 1, 2025. The CF will decrease from \$33.29 to \$32.35. A provision to provide a 2.5 percent increase to the CF was excluded.
- Medicare Advanced Alternative Payment Model Bonus Extension: Payments were not extended for the 2027 payment period. Incentive payments remain at 1.88 percent for 2026, reduced from 3.5 percent in 2025 and historically 5 percent.
- Medicare Sequester Extension: A proposed six-month extension of the 2 percent Medicare sequester was omitted.
- Separate National Provider Identification (NPI) Number for Off-Campus Hospital Outpatient Departments (HOPDs): A requirement for off-campus HOPDs to bill services using a separate NPI number was excluded.
- Pharmacy Benefit Manager (PBM) Reform:
 - A ban on spread pricing in Medicaid and a requirement that retail and specialty pharmacies comply with National Average Drug Acquisition Cost (NADAC) survey reporting, to ensure more accurate reimbursements at the acquisition cost for drugs
 - Requirements for prescription drug plan sponsors and PBMs under Medicare Part D to allow any pharmacy meeting reasonable contractual terms to join the plan's network
 - Part D delinking
 - Oversight and transparency provisions
 - An Employee Retirement Income Security Act (ERISA) pass-through requirement
- Reauthorization of the Rare Pediatric Priority Review Voucher (PRV) Program for five years
- Medicare Multi-Cancer Early Detection (MCED) Screening Coverage
- Extension of the Telehealth Safe Habor: Permit high-deductible health plan (HDHP) sponsors to reimburse telehealth and remote care services on a pre-deductible or first dollar coverage basis to participants with a health savings account (HSA).
- The Accelerating Kids Access to Care Act: A bill that will help speed the ability of children with complex medical conditions to seek specialty care at out-of-state centers of excellence.

The CR recently passed by Congress and signed into law by President Joe Biden includes several extensions and funding provisions that address expiring programs and payment adjustments. This included but is not limited to:

- Medicaid Disproportionate Share Hospitals (DSH): Medicaid DSH cuts have been eliminated through April 1, 2025
- Medicare Dependent Hospital (MDH) and Low Volume Adjustment (LVA) Programs: These programs are extended through March 31, 2025.
- Add-on Payment for Ambulance Services: The program is extended through March 31, 2025.
- Work Geographic Practice Cost Index (GPCI) Floor (calculation of MFPS payments): The program is extended through March 31, 2025.
- Medicare Acute Hospital Care at Home Waivers: The program is extended through March 31, 2025.



- Medicare Telehealth Coverage Waivers: Extensions through March 31, 2025 include:
 - Removing geographic and originating site requirements
 - Expanding the types of practitioners eligible to furnish telehealth
 - Extending telehealth services for Federally Qualified Health Centers (FQHCs) and rural health centers
 - Delaying the in-person requirement for Medicare mental health services
 - Allowing audio-only telehealth
 - Permitting telehealth to conduct face-to-face encounters prior to hospice eligibility recertification
- Community Health Centers (CHCs): \$1.05 billion in funding is provided through March 31, 2025.
- Teaching Health Centers Graduate Medical Education (THCGME): \$43.2 million in funding is allocated through March 31, 2025.
- Medicare Pay-As-You-Go (PAYGO) Sequester: Prevents a 4 percent mandatory Medicare payment reduction by "wiping clean" the pay as you go (PAYGO) scorecard.
- Disaster Relief Funding: \$29 billion in additional disaster relief funding to:
 - Support Federal Emergency Management Agency (FEMA) in obligating claims for hospitals and others related to the COVID-19 public health emergency
 - Address damages from the 2024 hurricanes
- Medicare Improvement Fund Reduction: Includes a \$1.96 billion reduction in the Medicare improvement fund to offset costs.

Healthcare in the 119th Congress

With Republicans leading both the House and Senate, health committees are set to pursue new agendas, likely aligning with the Trump Administration's "Make America Healthy Again" (MAHA) theme, particularly in areas like addressing chronic diseases. These committee agendas could focus on reforms to federal public health programs, advancing innovative healthcare technologies, modernizing Medicare payment models for physicians and providers, and supporting rural healthcare initiatives.

Other key areas of focus are expected to include:

- Price transparency
- No Suprises Act implementation
- Medicare Advantage (expansion and regulation)
- Affordable Care Act (ACA) (reemergence of limited benefit insurance coverage)
- Drug pricing (expansion of drug pricing lists)
- 340B Program (likely to be part of the PBM debate)
- Opioid epidemic funding or new restrictions
- Artificial Intelligence (AI) Regulation
- Rural Emergency Hospital Program modifications (e.g., swing beds, etc.)
- U.S. Department of Government Efficiency (DOGE) recommendations

2025 Congressional Schedule

Holland & Knight's 2025 Congressional calendar is available to view online.



Health Committees of Jurisdiction Guide

Mindful of slim Republican majorities with an increasingly deferential base, health priorities will likely adhere to the direction of Trump Administration leadership, including agency heads. However, the leadership of health committees of jurisdiction will play a notable role with their authority to bring legislation before a committee. Below is an inclusive list of the members of key healthcare committees of jurisdiction.

Senate

The Senate has five returning members with health professional backgrounds serving in the 119th Congress, all of whom are Republicans. Four are Doctors of Medicine (MD), and one is a Doctor of Optometry (OD). There have been no new additions to this cohort.

Committee/	Republicans	Democrats
Subcommittee		
Finance	Chair: Sen. Mike Crapo (R-Idaho)	Ranking Member: Sen. Ron Wyden (D-
Committee	Sen. Chuck Grassley (R-lowa)	Ore.)
	Sen. John Cornyn (R-Texas)	Sen. Maria Cantwell (D-Wash.)
	Sen. John Thune (R-S.D.)	Sen. Michael Bennet (D-Colo.)
	Sen. Tim Scott (R-S.C.)	Sen. Mark Warner (D-Va.)
	Sen. Bill Cassidy (R-La.)	Sen. Sheldon Whitehouse (D-R.I.)
	Sen. James Lankford (R-Okla.)	Sen. Maggie Hassan (D-N.H.)
	Sen. Steve Daines (R-Mont.)	Sen. Catherine Cortez Masto (D-Nev.)
	Sen. Todd Young (R-Ind.)	Sen. Elizabeth Warren (D-Mass.)
	Sen. John Barrasso (R-Wyo.)	Sen. Bernie Sanders (D-Vt.)
	Sen. Ron Johnson (R-Wis.)	Sen. Tina Smith (D-Minn.)
	Sen. Thom Tillis (R-N.C.)	Sen. Ben Ray Luján (D-N.M.)
	Sen. Marsha Blackburn (R-Tenn.)	Sen. Raphael Warnock (D-Ga.)
	Sen. Roger Marshall (R-Kan.)	Sen. Peter Welch (D-Vt.)
Health, Education,	Chair: Sen. Bill Cassidy (R-La.)	Ranking Member: Sen. Bernie Sanders (I-
Labor and Pensions	Sen. Rand Paul (R-Ky.)	Vt.)
Committee	Sen. Susan Collins (R-Maine)	Sen. Patty Murray (D-Wash.)
	Sen. Lisa Murkowski (R-Ark.)	Sen. Tammy Baldwin (D-Wis.)
	Sen. Markwayne Mullin (R-Okla.)	Sen. Chris Murphy (D-Conn.)
	Sen. Roger Marshall (R-Kan.)	Sen. Tim Kaine (Ď-Va.)
	Sen. Tommy Tuberville (R-Ala.)	Sen. Maggie Hassan (D-N.H.)
	Sen. Tim Scott (R-S.C.)	Sen. John Hickenlooper (D-Colo.)
	Sen. Josh Hawley (R-Mo.)	Sen. Ed Markey (D-Mass.)
	Sen. Jim Banks (R-Ind.)	Sen. Andy Kim (D-N.J.)
	Sen. Mike Crapo (R-Idaho)	Sen. Lisa Blunt Rochester (D-Del.)
	Sen. Marsha Blackburn (R-Tenn.)	Sen. Angela Alsobrooks (D-Md.)

House

Six new health professionals will serve in the 119th Congress:

- Rep. Sheri Biggs (R-S.C.): Family and Mental Health Nurse Practitioner
- Rep. Herb Conaway (D-N.J.): Internal Medicine Physician
- Rep. Maxine Dexter (D-Ore.): Pulmonary and Critical Care Physician
- Rep. Mike Kennedy (R-Utah): Family Physician
- Rep. Kelly Morrison (D-Minn.): Obstetrician-Gynecology
- Rep. Bob Onder (R-Mo.): Allergist-Immunologist



There are now 27 representatives in the House with health professional backgrounds, 17 of which are MDs. Of the 17 physicians, 11 are Republicans and six are Democrats.

Committee/	Republicans	Democrats
Subcommittee		
House Energy and	Chair: Rep. Brett Guthrie (R-Ky.)	Ranking Member: Rep. Frank Pallone (D-
Commerce	Rep. Robert E. Latta (R-Ohio)	N.J.)
Committee (Full	Rep. H. Morgan Griffith (R-Va.)	Rep. Diana DeGette (D-Colo.)
Roster)	Rep. Gus M. Bilirakis (R-Fla.)	Rep. Janice D. Schakowsky (D-III.)
	Rep. Richard Hudson (R-N.C.)	Rep. Doris O. Matsui (D-Calif.)
	Rep. Earl L. "Buddy" Carter (R-Ga.)	Rep. Kathy Castor (D-Fla.)
	Rep. Gary J. Palmer (R-Ala.)	Rep. Paul Tonko (D-N.Y.)
	Rep. Neal P. Dunn (R-Fla.)	Rep. Yvette D. Clarke (D-N.Y.)
	Rep. Dan Crenshaw (R-Texas)	Rep. Raul Ruiz (D-Calif.)
	Rep. John Joyce (R-Pa.)	Rep. Scott H. Peters (D-Calif.)
	Rep. Randy K. Weber (R-Texas)	Rep. Debbie Dingell (D-Mich.)
	Rep. Rick W. Allen (R-Ga.)	Rep. Marc A. Veasey (D-Texas)
	Rep. Troy Balderson (R-Ohio)	Rep. Robin L. Kelly (D-III.)
	Rep. Russ Fulcher (R-Idaho)	Rep. Nanette Diaz Barragán (D-Calif.)
	Rep. August Pfluger (R-Texas)	Rep. Darren Soto (D-Fla.)
	Rep. Diana Harshbarger (R-Tenn.)	Rep. Kim Schrier (D-Wash.)
	Rep. Mariannette Miller-Meeks (R-Iowa)	Rep. Lori Trahan (D-Mass.)
	Rep. Kat Cammack (R-Fla.)	Rep. Lizzie Fletcher (D-Texas)
	Rep. Jay Obernolte (R-Calif.)	Rep. Alexandria Ocasio-Cortez (D-N.Y.)
	Rep. John James (R-Mich.)	Rep. Jake Auchincloss (D-Mass.)
	Rep. Gabe Evans (R-Colo.)	Rep. Troy Carter (D-La.)
	Rep. Erin Houchin (R-Ind.)	Rep. Robert Menendez (D-N.J.)
	Rep. Russell Fry (R-S.C.)	Rep. Kevin Mullin (D-Calif.)
	Rep. Laurel Lee (R-Fla.)	Rep. Greg Landsman (D-Ohio)
	Rep. Craig Goldman (R-Texas)	Rep. Jennifer McClellan (D-Va.)
	Rep. Tom Kean (R-N.J.)	
	Rep. Julie Fedorchak (R-N.D.)	
	Rep. Nick Langworthy (R-N.Y.)	
	Rep. Mike Rulli (R-Ohio)	
Health Subcommittee	Rep. Cliff Bentz (R-Ore.)	Panking Mambar: Pan DaGatta (D.Cala)
nealth Subcommittee	Chair: Rep. Carter (R-Ga.) Vice Chair: Rep. Dunn (R-Fla.)	Ranking Member: Rep. DeGette (D-Colo.) Rep. Ruiz (D-Calif.)
	Rep. Griffith (R-Va.)	Rep. Dingell (D-Minn.)
	Rep. Bilirakis (R-Fla.)	Rep. Kelly (D-III.)
	Rep. Crenshaw (R-Texas)	Rep. Barragán (D-Calif.)
	Rep. Joyce (R-Pa.)	Rep. Schrier (D-Wash.)
	Rep. Balderson (R-Ohio)	Rep. Trahan (D-Mass.)
	Rep. Harshbarger (R-Tenn.)	Rep. Veasey (D-Texas)
	Rep. Miller-Meeks (R-lowa)	Rep. Fletcher (D-Texas)
	Rep. Cammack (R-Fla.)	Rep. Ocasio-Cortez (D-N.Y.)
	Rep. Obernolte (R-Calif.)	Rep. Auchincloss (D-Mass.)
	Rep. James (R-Minn.)	Rep. Carter (D-La.)
	Rep. Bentz (R-Ore.)	Rep. Landsman (D-Ohio)
	Rep. Houchin (R-Ind.)	Rep. Pallone (D-N.J.), Ex-Officio
	Rep. Langworthy (R-N.Y.)	, , , , , , ,
	Rep. Kean (R-N.J.)	
	Rep. Rulli (R-Ohio)	
	Rep. Guthrie (R-Ky.), Ex-Officio	

$Holl and \&\,Knight$



Oversight and Chair: Rep. Palmer (R-Ala.) Ranking Member: Rep. Cla	
	rke (D-N.Y.)
Investigations Vice Chair: Rep. Balderson (R-Ohio) Rep. DeGette (D-Colo.)	
Subcommittee Rep. Griffith (R-Va.) Rep. Tonko (D-N.Y.)	
Rep. Dunn (R-Fla.) Rep. Trahan (D-Mass.)	
Rep. Crenshaw (R-Texas) Rep. Fletcher (D-Texas)	
Rep. Weber (R-Texas) Rep. Ocasio-Cortez (D-N.Y.)	
Rep. Allen (R-Ga.) Rep. Mullin (D-Calif.)	
Rep. Fulcher (R-Idaho) Rep. Pallone (D-N.J.), Ex-Of	ficio
Rep. Rulli (R-Ohio)	
Rep. Guthrie (KY), Ex-Officio	
House Ways and Chair: Rep. Jason Smith (R-Mo.) Ranking Member: Rep. Ric	hard Neal (D-
Means Committee Rep. Vern Buchanan (R-Fla.)	
Rep. Adrian Smith (R-NE) Rep. Lloyd Doggett (D-Texas	3)
Rep. Mike Kelly (R-PA) Rep. Mike Thompson (D-Cal	
Rep. David Schweikert (R-Ariz.) Rep. John B. Larson (D-Con	
Rep. Darin LaHood (R-III.) Rep. Danny K. Davis (D-III.)	11.)
Rep. Jodey Arrington (R-Texas) Rep. Linda T. Sánchez (D-Carrington)	alif \
	alli.)
Rep. Ron Estes (R-Kan.) Rep. Terri A. Sewell (D-Ala.)	ob \
Rep. Lloyd Smucker (R-Pa.) Rep. Suzan DelBene (D-Wa	sn.)
Rep. Kevin Hern (R-Okla.) Rep. Judy Chu (D-Calif.)	
Rep. Carol Miller (R-W.Va.) Rep. Gwen Moore (D-Wis.)	
Rep. Greg Murphy (R-N.C.) Rep. Don Beyer (D-Va.)	
Rep. David Kustoff (R-Tenn.) Rep. Dwight Evans (D-Pa.)	
Rep. Brian Fitzpatrick (R-Pa.) Rep. Brad Schneider (D-III.)	
Rep. Greg Steube (R-Fla.) Rep. Jimmy Panetta (D-Calif	
Rep. Claudia Tenney (R-N.Y.) Rep. Jimmy Gomez (D-Calif	
Rep. Michelle Fischbach (R-Minn.) Rep. Steven Horsford (D-Ne	v.)
Rep. Blake Moore (R-Utah) Rep. Brendan Boyle (D-Pa.)	
Rep. Beth Van Duyne (R-Texas) Rep. Stacey Plaskett (D-VI)	
Rep. Randy Feenstra (R-lowa) Rep. Tom Suozzi (D-N.Y.)	
Rep. Nicole Malliotakis (R-N.Y.)	
Rep. Mike Carey (R-Ohio)	
Rep. Aaron Bean (R-Fla.)	
Rep. Max Miller (R-Ohio)	
Rep. Nathaniel Moran (Ŕ-Texas)	
Rep. Rudy Yakym (R-Ind.)	
Health Subcommittee Chair: Rep. Buchanan (R-Fla.) Ranking Member: Rep. Do	ggett (D-Texas)
Rep. Smith (R-Neb.) Rep. Thompson (D-Calif.)	99011 (2 10/10/0)
Rep. Kelly (R-Pa.) Rep. Chu (D-Calif.)	
Rep. Murphy (R-N.C.) Rep. Evans (D-Pa.)	
Rep. Hern (R-Okla.) Rep. Davis (D-III.)	
Rep. Miller (R-W.Va.) Rep. Horsford (D-Nev.)	
Rep. Fitzpatrick (R-Pa.) Rep. Boyle (D-Pa.)	
Rep. Fitzpatrick (R-Fa.) Rep. Boyle (D-Fa.) Rep. Sánchez (D-Calif.)	
Rep. Moore (Utah)	
Rep. Kustoff (R-Tenn)	
Rep. Steube (R-Fla.)	
Oversight Chair: Rep. Schweikert (AZ) Ranking Member: Rep. Set	well (AL)
Subcommittee Rep. Fischbach (R-Minn.) Rep. Chu (D-Calif)	
Rep. Van Duyne (R-Texas) Rep. DelBene (D-Wash.)	
Rep. Malliotakis (R-N.Y.)	
Rep. Yakym (R-Ind.) Rep. Doggett (D-Texas)	
Rep. Miller (R-Ohio)	
Rep. Bean (R-Fla.)	
Rep. Moran (R-Texas)	

$Holl and \&\,Knight$



House	Chair: Rep. Tom Cole (R-Okla.)	Ranking Member: Rep. Rosa DeLauro (D-
Appropriations	Rep. Hal Rogers (R-Ky.)	Conn.)
Committee	Rep. Robert Aderholt (R-Ala.)	Rep. Steny Hoyer (D-Md.)
	Rep. Mike Simpson (R-Idaho)	Rep. Marcy Kaptur (D-Ohio)
	Rep. John Carter (R-Texas)	Rep. Sanford Bishop (D-Ga.)
	Rep. Ken Calvert (R-Calif.)	Rep. Betty McCollum (D-Minn.)
	Rep. Mario Diaz-Balart (R-Fla.)	Rep. Debbie Wasserman Schultz (D-Fla.)
	Rep. Steve Womack (R-Ark.)	Rep. Henry Cuellar (D-Texas)
	Rep. Chuck Fleischmann (R-Tenn.)	Rep. Chellie Pingree (D-Maine)
	Rep. David Joyce (R-Ohio)	Rep. Mike Quigley (D-III.)
	Rep. Andy Harris (R-Md.)	Rep. Grace Meng (D-N.Y.)
	Rep. Mark Amodei (R-Nev.)	Rep. Mark Pocan (D-Wis.)
	Rep. David Valadao (R-Calif.)	Rep. Pete Aguilar (D-Calif.)
	Rep. Dan Newhouse (R-Wash.)	Rep. Lois Frankel (D-Fla.)
	Rep. John Moolenaar (R-Mich.)	Rep. Bonnie Watson Coleman (D-N.J.)
	Rep. John Rutherford (R-Fla.)	Rep. Norma Torres (D-Calif.)
	Rep. Ben Cline (R-Va.)	Rep. Ed Case (D-Hawaii)
	Rep. Guy Reschenthaler (R-Pa.)	Rep. Adriano Espaillat (D-N.Y.)
	Rep. Ashley Hinson (R-Iowa)	Rep. Josh Harder (D-Calif.)
	Rep. Tony Gonzales (R-Texas)	Rep. Lauren Underwood (D-III.)
	Rep. Julia Letlow (R-La.)	Rep. Susie Lee (D-Nev.)
	Rep. Michael Cloud (R-Texas)	Rep. Joseph Morelle (D-N.Y.)
		Rep. James E. Clyburn (D-S.C.)
	Rep. Michael Guest (R-Miss.)	, ,
	Rep. Ryan Zinke (R-Mont.)	Rep. Mike Levin (D-Calif.)
	Rep. Andrew Clyde (R-Ga.)	Rep. Madeleine Dean (D-Pa.)
	Rep. Stephanie Bice (R-Okla,)	Rep. Veronica Escobar (D-Texas)
	Rep. Scott Franklin (R-Fla.)	Rep. Frank Mrvan (D-Ind.)
	Rep. Jake Ellzey (R-Texas)	Rep. Marie Gluesenkamp Perez (D-Wash.)
	Rep. Juan Ciscomani (R-Ariz.)	Rep. Glenn Ivey (D-Md.)
	Rep. Chuck Edwards (R-N.C.)	
	Rep. Mark Alford (R-Mo.)	
	Rep. Nick LaLota (R-N.Y.)	
	Rep. Dale Strong (R-Ala.)	
	Rep. Celeste Maloy (R-Utah)	
	Rep. Riley Moore (R-W.Va.)	
Agriculture, Rural	Chair: Rep. Harris (R-Md.)	Ranking Member: Rep. Bishop, Jr. (D-Ga.)
Development, Food	Vice Chair: Rep. Franklin (R-Fla.)	Rep. Pingree (D-Maine)
and Drug	Rep. Aderholt (R-Ala.)	Rep. Underwood (D-III.)
Administration and	Rep. Valadao (R-Calif.)	Rep. Gluesenkamp Perez (D-Wash.)
Related Agencies	Rep. Moolenaar (R-Minn.)	Rep. Kaptur (D-Ohio)
Nelated Ayelloles	Rep. Newhouse (R-Wash.)	Rep. Wasserman Schultz (D-Fla.)
	Rep. Letlow (R-La.)	Rep. DeLauro (D-Conn.), Ex-Officio
	Rep. Cline (R-Va.)	
1 1 11 101 1	Rep. Hinson (R-lowa)	
Labor, Health and	Chair: Rep. Aderholt (R-Ala.)	Ranking Member: Rep. DeLauro (D-Conn.)
Human Services,	Vice Chair: Rep. Letlow (R-La.)	Rep. Hoyer (D-Md.)
Education and Related	Rep. Simpson (R-Idaho)	Rep. Pocan (D-Wis.)
Agencies	Rep. Harris (R-Md.)	Rep. Frankel (D-Fla.)
	Rep. Fleischmann (R-Tenn.)	Rep. Watson Coleman (D-N.J.)
	Rep. Moolenaar (R-Minn.)	Rep. Harder (D-Calif.)
	Rep. Clyde (R-Ga.)	Rep. Dean (D-Pa.)
	Rep. Ellzey (R-Texas)	,
	Rep. Bice (R-Okla.)	
	Rep. Moore (R-W.Va.)	
	Trop. Moore (In-vv. va.)	



Trump Administration Outlook

Starting day one, the Trump Administration will issue a bevy of EOs and other policy announcements outlining new policy mandates and priorities for his administration, including those related to healthcare.

Predictions of what he may focus on within the health realm are detailed below. President-Elect Trump is also expected to issue policy announcements on new healthcare priorities relating to chronic disease and the MAHA initiative. Additionally, initial announcements may offer further details about the DOGE, a proposed presidential advisory commission focused on reducing federal spending and government size, and how this cost-cutting initiative might impact healthcare programs.

EOs

There are several items of interest of the incoming Trump Administration that could be established through a slew of EOs. A few potential contenders include EOs on essential medicines, chronic disease and AI. President-Elect Trump has announced his intention to reinstate an EO from August 2020 that focuses on the procurement of essential medicines. This policy prevented federal agencies from procuring essential medicines from trading partners as a way to bolster domestic manufacturing. However, healthcare entities should watch closely for its return with drug shortages remaining at high levels and supply chains continuing to experience shocks following the COVID-19 pandemic.

President-Elect Trump expressed plans to establish a special Presidential Commission to determine what is causing the decades-long increase in chronic illnesses, which could be established through an EO. President-Elect Trump is also expected to issue EOs regarding gender affirming care, including access to medications for children and even adults, as well as order studies regarding the impact of gender affirming care on the behaviors of patients.

President-Elect Trump has publicly discussed imposing a 60 percent tariff on all goods from China. Revoking China's Most Favored Nation status could result in tariffs from anywhere between 35 percent to 100 percent, including on medical products such as active pharmaceutical ingredients (APIs). President-Elect Trump is also expected to rescind EOs regarding AI, which may have immediate impacts on how AI is used in the clinical setting. President-Elect Trump has referred to President Biden's EO on the safe development and use of AI as akin to censorship, which may jeopardize projects underway at HHS to study AI's use in providing safe patient care or protecting against the creation of dangerous pathogens using gene synthesis.

Importantly, the U.S. Supreme Court's ruling in *Loper Bright Enterprises v. Raimondo* overturned longstanding deference given to administrative agencies in the rulemaking process. In practice, this change could increase the likelihood of court challenges to federal agency rulemaking or interpretations directed by an EO. This will be the first incoming administration following the *Loper Bright* Supreme Court decision.

Deregulatory Agenda – What Happens to Biden Administration Regulations?

The Trump Administration is expected to halt the consideration of all rules and regulations that remained pending during the final months of the Biden Administration. Early announcements regarding the rollback of regulations will be closely monitored. Typically, the president's chief of staff issues a regulatory freeze directive to executive departments and agencies, instructing them to withdraw rules submitted to the Office of the Federal Register (OFR) but not yet published. For rules that have been published but have not yet taken effect, their effective dates are often postponed by 60 days to allow for review. The pause or "regulatory freeze" will allow the incoming administration to review and determine whether the administration wants to revise, rescind or continue pursuing any pending regulation. This does not typically apply to rules required under statute or by judicial review. Several notable healthcare regulations are subject to additional scrutiny, including the nursing home staffing rule, Health Insurance Portability and Accountability Act (HIPAA) reproductive rights and Section 1557.

Under the Congressional Review Act (CRA), an incoming administration can review regulations published in the final months of the previous administration, dating back to Aug. 1, 2024, for this cycle. Rules will not be available for review under the CRA if they are published in the *Federal Register* and submitted to both the House and Senate before the lookback date. There are over 78 healthcare regulations up for potential review, with many speculating on which items may be evaluated. The attached spreadsheet highlights final regulations potentially available for congressional review.



Pending Regulations

Several regulations of interest to the healthcare sector remain pending and may be released prior to President Biden's departure from the White House. This includes rules on Healthcare System Resiliency and Modernization, Amendments to Rules Governing Organ Procurement Organizations, Independent Dispute Resolution (IDR) Operations Rule under the No Surprises Act, and the 2026 Medicare Advantage policy and technical rule. Notably, if these rules are released imminently, they would all be subject to the aforementioned review process. Additionally, statutorily, Centers for Medicare & Medicaid Services (CMS) must release the initial price applicability year (IPAY) 2027 list of 15 additional drugs for negotiation by Feb. 1, 2025, but it could be published anytime between Jan. 16, 2025, and Feb. 1, 2025.

Potential HHS Secretary Hearing Dates

Jan. 23, 2025

Health, Education, Labor and Pensions (HELP) Committee: Robert F. Kennedy Jr. (HHS Secretary) (reported, but not posted)

Jan. 29, 2025

■ Finance Committee: Robert F. Kennedy Jr. (HHS Secretary) (not confirmed, paperwork still in process)